In Vivo Study On The Reversal Of Cisplatin Resistance Of Ovarian Cancer By GSTπ Antisence Oligonucleotide

Objective: To investigate the reversal of cisplatin resistance of ovarian cancer by GST π antisence oligonucleotide in vivo.Methods: The cisplatin-resistant ovarian cancer cell line COC1/DDP was cultured and injected into the abdominal cavity of nude mice to establish the malignant ascites model. The mice were devided randomly into three groups .Two weeks after the establishment of the model and then treated respectively with DDP, ASODN+DDP and missense SODN+DDP. The change of abdomen circumference and the difference of life span of the nude mice were observed. The tumor tissue was detected under microscope, the expression of GST π was detected by immunohistochemistry and RT-PCR.Results: (1) After one week of the treatment, the abdomen circumference of ASODN + DDP group were obviously decreased,while the abdomen circumference of DDP group and missense SODN+DDP group were gradually increased. And the life span of ASODN+DDP group was obviously longer than that of the other two groups (P<0.05). (2) In the ASODN + DDP group, the number of tumor cells was less and the expression of GST π was weak under the microscope. (3)Compared with the other two groups, the expression level of GST π mRNA was significantly inhibited in the ASODN + DDP group(P<0.05).Conclusion: GST π ASODN can effectively reverse the resistance of ovarian cancer to cisplatin and increase their drug sensitivity.